Stocktoria
PUMA BIOTECHNOLOGY, INC. PBYI
PUMA BIOTECHNOLOGY, INC. (PBYI) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $228.4M at a 13.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.06 — grey zone (between the usual thresholds). A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.376 |
| Retained earnings / assets | -5.935 |
| EBIT / assets | 0.172 |
| Equity / liabilities | 1.516 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| PBYI | PUMA BIOTECHNOLOGY, INC. | 6/9 | -14.13 | 13.3 | -0.9% |
| LFVN | Lifevantage Corp | 6/9 | -0.45 | 8.5 | +14.2% |
| ANAB | ANAPTYSBIO, INC | 5/9 | -0.3 | — | +157% |
| AKBA | Akebia Therapeutics, Inc. | 5/9 | -12.49 | — | +47.5% |
| IDYA | IDEAYA Biosciences, Inc. | 3/9 | 12.9 | — | — |
| VNDA | Vanda Pharmaceuticals Inc. | 2/9 | 0.13 | — | +8.7% |
| AMRN | AMARIN CORP PLCUK | 5/9 | -2.07 | — | -6.5% |
About PUMA BIOTECHNOLOGY, INC.
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distributor networks. The company has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
FAQ
Is PBYI financially healthy?
PUMA BIOTECHNOLOGY, INC.'s Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does PBYI pay a dividend?
No, PUMA BIOTECHNOLOGY, INC. does not currently pay a dividend.
How profitable is PBYI?
In FY2025, PUMA BIOTECHNOLOGY, INC. had a net margin of 13.6% and a return on equity of 23.9%.
What is PBYI's P/E ratio?
PUMA BIOTECHNOLOGY, INC.'s trailing price-to-earnings (P/E) ratio is about 13.3×, based on its latest annual earnings.
What is the analyst price target for PBYI?
The average Wall-Street price target for PUMA BIOTECHNOLOGY, INC. is $5.00, about 43.8% below the recent price, from 1 analysts.
Is PBYI a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on PUMA BIOTECHNOLOGY, INC.: a Piotroski F-score of 6/9, an Altman Z″ in the distress zone, a P/E of about 13.3×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.